|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,986.50 DKK | -1.32% |
|
-1.17% | +33.10% |
| 12-12 | Genmab Finalizes Tender Offer for Dutch Biotech Merus | MT |
| 12-12 | Genmab Completes Acquisition of Merus – Bolsters Portfolio with New Cancer Treatment | FW |
| Capitalization | 122B 19.28B 16.38B 15.32B 14.36B 26.5B 1,753B 29.05B 179B 69.05B 824B 72.32B 70.82B 2,985B | P/E ratio 2025 * |
16.9x | P/E ratio 2026 * | 20.4x |
|---|---|---|---|---|---|
| Enterprise value | 98.97B 15.59B 13.24B 12.39B 11.61B 21.44B 1,418B 23.49B 145B 55.84B 666B 58.49B 57.28B 2,414B | EV / Sales 2025 * |
4.16x | EV / Sales 2026 * | 3.28x |
| Free-Float |
95.94% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Genmab A/S
| 1 day | -1.32% | ||
| 1 week | -1.17% | ||
| Current month | -2.57% | ||
| 1 month | +1.69% | ||
| 3 months | +11.95% | ||
| 6 months | +34.72% | ||
| Current year | +33.10% |
| 1 week | 1,979 |  | 2,055 |
| 1 month | 1,913.5 | | 2,111 |
| Current year | 1,157 | | 2,153 |
| 1 year | 1,157 | | 2,153 |
| 3 years | 1,157 | | 3,093 |
| 5 years | 1,157 | | 3,327 |
| 10 years | 605.5 | | 3,327 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 47 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 74 | 2014-12-31 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 3.64% | 1,412 M€ | +0.17% | - |
| 0.75% | 26 M€ | +10.53% | - |
| 0.56% | 1,101 M€ | +8.55% | - |
| 0.45% | 31 M€ | +2.81% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.32% | -1.17% | +37.71% | -34.93% | 19.52B | |
| +0.41% | -5.44% | +19.94% | +98.80% | 52.08B | |
| +1.90% | +3.35% | +173.43% | +950.63% | 42B | |
| -2.29% | -3.31% | +58.55% | +12.70% | 38.48B | |
| -1.68% | -3.78% | -19.25% | -47.37% | 22.56B | |
| +0.19% | -4.17% | +91.09% | -35.90% | 17.21B | |
| -0.77% | -0.60% | +87.11% | +187.02% | 13.75B | |
| -0.86% | +1.23% | -7.76% | +377.29% | 13.4B | |
| -0.99% | -2.47% | +126.35% | - | 12.06B | |
| -1.07% | +0.12% | +78.32% | +769.23% | 12.73B | |
| Average | -0.58% | -2.83% | +64.55% | +253.05% | 24.38B | |
| Weighted average by Cap. | -0.35% | -2.60% | +65.88% | +261.56% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 23.81B 3.75B 3.19B 2.98B 2.79B 5.16B 341B 5.65B 34.82B 13.43B 160B 14.07B 13.78B 581B | 27.48B 4.33B 3.68B 3.44B 3.23B 5.95B 394B 6.52B 40.19B 15.51B 185B 16.24B 15.91B 670B |
| Net income | 7.48B 1.18B 1B 936M 878M 1.62B 107B 1.78B 10.94B 4.22B 50.34B 4.42B 4.33B 182B | 6.56B 1.03B 878M 821M 770M 1.42B 93.95B 1.56B 9.59B 3.7B 44.14B 3.88B 3.8B 160B |
| Net Debt | -23.4B -3.69B -3.13B -2.93B -2.75B -5.07B -335B -5.56B -34.22B -13.2B -157B -13.83B -13.54B -571B | -32.23B -5.08B -4.31B -4.03B -3.78B -6.98B -462B -7.65B -47.13B -18.18B -217B -19.05B -18.65B -786B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-16 | 1,986.50 kr | -1.32% | 97,098 |
| 25-12-15 | 2,013.00 kr | -0.10% | 127,929 |
| 25-12-12 | 2,015.00 kr | -1.52% | 87,461 |
| 25-12-11 | 2,046.00 kr | +2.74% | 80,332 |
| 25-12-10 | 1,991.50 kr | -0.92% | 120,520 |
Delayed Quote Nasdaq Copenhagen, December 16, 2025 at 11:20 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition